Deal facts
- Buyer
- Ipsen
- Target
- Memo Therapeutics AG
- Deal value
- EUR 200,000,000
- Announced
- 2 July 2026
- Status
- Firm intention
- Sector
- Healthcare
- Country
- Switzerland
- Consideration
- cash, deferred
Sources
Ipsen has agreed to acquire Memo Therapeutics AG in a strategic acquisition valued at EUR 200 million. The transaction involves a headline offer comprising both cash and deferred consideration elements. This deal brings together a French buyer and a Swiss target within the healthcare sector. The announcement was made on 2 July 2026, marking a significant expansion for the acquiring entity into the Swiss biotechnology landscape.
The proposed transaction remains in the firm intention stage as of the latest available reporting. No completion date has been confirmed at this time. Regulatory approvals and other standard closing conditions are expected to be required before the deal can be finalised. The parties are currently proceeding with the necessary due diligence and negotiation steps to advance the agreement towards a definitive conclusion.
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
1 update- Firm intention
Sale of Memo Therapeutics AG
Disclaimer* Schroders Capital Global Innovation Trust plc (the "Company") is pleased to announce that its portfolio company Memo Therapeutics AG ("Memo"), a Swiss biotechnology company, has entered into a definitive share purchase agreement under which Ipsen has agreed to acquire Memo's potravitug programme. The anticipated acquisition is focused on potravitug, a first-in-clas
LSE RNS
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Cronos Group Inc. to acquire CanAdelaar B.V.
Cronos Group Inc. has agreed to acquire CanAdelaar B.V. in a strategic acquisition within the healthcare sector. The Canadian buyer will purchase the Dutch target for a…
- Buyer
- Cronos Group Inc.
- Target
- CanAdelaar B.V.
- Deal value
- EUR 57,500,000
- Deal type
- strategic acquisition
Alaunos Therapeutics, Inc. to acquire Velaris Therapeutics, Inc.
Alaunos Therapeutics, Inc. has agreed to acquire Velaris Therapeutics, Inc. in a strategic acquisition. The transaction was announced on 13 October 2026 and was complete…
- Buyer
- Alaunos Therapeutics, Inc.
- Target
- Velaris Therapeutics, Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
STERIS Corporation to acquire Xodus Medical, Inc.
STERIS Corporation has agreed to acquire Xodus Medical, Inc. in a strategic transaction valued at two billion US dollars. The healthcare deal was announced on 11 October…
- Buyer
- STERIS Corporation
- Target
- Xodus Medical, Inc.
- Deal value
- USD 2,100,000,000
- Deal type
- strategic acquisition
Hepion Pharmaceuticals, Inc. to acquire Gravitas Life Sciences, LLC
Hepion Pharmaceuticals, Inc. has agreed to acquire Gravitas Life Sciences, LLC in a strategic acquisition. The transaction, valued at 4.25 million US dollars, was comple…
- Buyer
- Hepion Pharmaceuticals, Inc.
- Target
- Gravitas Life Sciences, LLC
- Deal value
- USD 4,250,000
- Deal type
- strategic acquisition
Buyer history
Ipsen
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive